Abstract:Aims: Numerous markers have been identified as useful predictors of major adverse cardiac events (MACE) in patients with suspected acute coronary syndrome (ACS). However, only little is known about the relative benefit of the single markers in risk stratification and the best combination for optimising prognostic power. The aim of the present study was to define the role of the emerging cardiovascular risk marker lipoprotein-associated phospholipase A2 (Lp-PLA2) in a multi-marker approach in combination with troponin I (TnI), NT-proBNP, high sensitivity (hs)CRP, and D-dimer in patients with ACS. Methods and results: A total of 429 consecutive patients (age 60.5+/-14.1 years, 60.6% male) who were admitted to the emergency room with suspected ACS were analysed in the study. Biochemical markers were measured by immunoassay techniques. All patients underwent point-of-care TnI testing and early coronary angiography if appropriate, in accordance with the current guidelines. Classification and regression trees (CART) and logistic regression techniques were employed to determine the relative predictive power of markers for the primary end-point defined as any of the following events within 42 days after admission: death, non-fatal myocardial infarction, unstable AP requiring admission, admission for decompensated heart failure or shock, percutaneous coronary intervention, coronary artery bypass grafting, life threatening arrhythmias or resuscitation. The incidence of the primary end-point was 13.1%, suggesting a mild to moderate risk population. The best overall risk stratification was obtained using NT-proBNP at a cut-off of 5000 pg/mL (incidence of 40% versus 10.3%, relative risk (RR) 3.9 (95% CI 2.4-6.3)). In the remaining lower risk group with an incidence of 10.3%, further separation was performed using TnI (cut-off 0.14 microg/L; RR=3.1 (95% CI 1.7-5.5) 23.2% versus 7.5%) and again NT-proBNP (at a cut-off of 140 ng/L) in patients with negative TnI (RR=3.2 (95% CI 1.3-7.9), 11.7% versus 3.6%). A final significant stratification in patients with moderately elevated NT-proBNP levels was achieved using Lp-PLA2 at a cut-off of 210 microg/L) (17.9% versus 6.9%; RR=2.6 (95% CI 1.1-6.6)). None of the clinical or ECG variables of the TIMI (Thrombolysis In Myocardial Infarction) risk score provided comparable clinically relevant information for risk stratification. Conclusions: In the setting of stateof- the-art coronary care for patients with suspected ACS in the emergency room, NT-proBNP, troponin I, and Lp-PLA2 are effective independent markers for risk stratification that proved to be superior to the TIMI risk score. Lp-PLA2 turned out to be a more effective risk marker than hsCRP in these patients.

Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study

Value of Matrix Metalloproteinase - 9 and Ischemia - Modified Albumin for Diagnosis of Coronary Heart Disease

Lipoprotein-Associated Phospholipase A 2 Activity Level May Be Complementary to Cardiactroponin I As a Biomarker for Acute Myocardial Infarction in Chinese Patients with Chest Pain

Association of lipoprotein-associated phospholipase A 2 with characteristics of vulnerable coronary atherosclerotic plaques

Value of serum lipoprotein(a) measurement in patients with acute coronary syndrome

Correlation between lipoprotein-associated phospholipase A2 and main risk factors in unstable angina pectoris patients

Evaluation of lipoprotein‐associated phospholipase A2, serum amyloid A, and fibrinogen as diagnostic biomarkers for patients with acute cerebral infarction

Ischemia-modified albumin in stable coronary atherosclerotic heart disease: clinical diagnosis and risk stratification.

Association Between Plasma Lysophosphatidic Acid and Coronary Stenosis with Coronary Heart Disease

Lipoprotein-associated phospholipase A2 activity levels is associated with artery to artery embolism in symptomatic intracranial atherosclerotic disease

Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis

Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II)

Clinical Utility of the Serum Level of Lipoprotein-Related Phospholipase A2 in Acute Ischemic Stroke With Cerebral Artery Stenosis

The clinical application value of serum hs-CRP, IL-1β and Lp-PLA2 in ACS

Correlation of Lipoprotein-Associated Phospholipase A2 and Cerebral Microbleeds in Patients with Acute Ischaemic Stroke

The Relationship Between the Level of Serum ESM-1 and Lp-PLA2 in Patients With Acute ST-Segment Elevation Myocardial Infarction

Association Between Plasma Lipoprotein-Associated Phospholipase A2 and Plaque Vulnerability in TIA Patients With Unilateral Middle Cerebral Artery Stenosis

Ischemia-modified albumin and C reactive protein in diagnosis of acute coronary syndromes

Elevated Plasma Lipoprotein-Associated Phospholipase A(2) Activity is Associated with Plaque Rupture in Patients with Coronary Artery Disease

Ischemia-modified Albumin Measured with Ultra-Filtration Assay in Early Diagnosis of Acute Coronary Syndrome.

Ischemia-modified Albumin in Stable Coronary Atherosclerotic Heart Disease